Translation: Original published in Finnish on 7/14/2026 at 7:57 am EEST.

On Monday, Faron provided an update on its investigator-initiated trials (IIT) portfolio evaluating bexmarilimab. Key updates were that the combination treatment in the BLAZE trial was changed to nivolumab, the BEXAR trial received regulatory approval, and the bexmarilimab cohort in the FINPROVE trial was shut down. IITs offer new potential indications for bexmarilimab and support the drug candidate’s long-term value. However, from Faron’s investment perspective, they are secondary to the company’s own BEXERA trial, which focuses on blood cancers.

Progress in solid tumor research

In the BLAZE trial, bexmarilimab is being evaluated in combination with the approved anti-PD-1 inhibitor nivolumab in patients with lung cancer or melanoma who have developed resistance to prior anti-PD-1-based therapy. We believe selecting nivolumab as the combination drug is scientifically valid because its efficacy and safety are well-known, which will make it easier to verify the additional benefits provided by bexmarilimab. The study has received the necessary approvals and is progressing towards recruiting the first patient. The BEXAR trial, which focuses on soft tissue sarcoma, has also received regulatory and ethical approvals and is advancing towards patient recruitment.

FINPROVE tests discontinued, blood cancer studies advance

The bexmarilimab cohort in the FINPROVE study being conducted in Finland will not proceed following Fimea’s review, as the platform trial is designed primarily for marketed therapies. Meanwhile, the BEAM-X and City of Hope trials, which focus on blood cancers (AML and MDS), are progressing as planned toward regulatory submissions.